Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2026)

Maxcyte (MXCT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $194.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 15.43% year-over-year to $194.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $830.2 million (down 14.37% YoY) and the FY2025 annual result came in at $202.5 million, down 15.44% from the prior year.
• Liabilities and Shareholders Equity eased to $194.5 million in Q1 2026 per MXCT's latest filing, from $202.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $291.0 million in Q1 2022 and bottomed at $194.5 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $257.9 million (2024), against an average of $252.9 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 211.1%; it then declined 15.44% in 2025.
• Tracing MXCT's Liabilities and Shareholders Equity over 5 years: stood at $286.7 million in 2022, then slipped by 6.41% to $268.3 million in 2023, then declined by 10.74% to $239.5 million in 2024, then fell by 15.44% to $202.5 million in 2025, then decreased by 3.97% to $194.5 million in 2026.
• Per Business Quant, the three latest MXCT Liabilities and Shareholders Equity figures stand at $194.5 million (Q1 2026), $202.5 million (Q4 2025), and $213.5 million (Q3 2025).

Peer Comparison